| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Research (Dr. Leppert, B. Erne, and C. Grygar), Neurology (Drs. Leppert, Huber, Steck, and Fuhr), and Pathology (Dr. Probst), University Hospitals, Basel, Switzerland; Hôpital de Bicêtre (Dr. Said), Paris, France; British Biotech Pharmaceuticals, Ltd. (Dr. Miller); and Laboratory of Physiology (Dr. Hughes), University of Oxford, UK.
Address correspondence and reprint requests to Dr. David Leppert, Department of Neurology, University Hospitals Basel, Hebelstrasse 20, CH-4031 Basel, Switzerland; e-mail: leppert{at}ubaclu.unibas.ch
OBJECTIVE: To determine the expression pattern and cellular source of matrix metalloproteinases (MMPs) in chronic inflammatory demyelinating polyneuropathy (CIDP) and nonsystemic vasculitic neuropathy (NSVN).
BACKGROUND: MMPs are endopeptidases involved in tissue destruction and infiltration by immune cells in multiple sclerosis and Guillain-Barré syndrome. Enzyme inhibitors of MMPs attenuate clinical symptoms in corresponding animal models of these diseases. MMP inhibition may therefore be a novel approach for the treatment of CIDP and NSVN. However, the spectrum of MMPs expressed in chronic inflammatory neuropathies has not been established.
METHODS: The expression of MMP-2, MMP-3, MMP-7, and MMP-9 in T cells, macrophages, and stromal cells in CIDP, NSVN, and noninflammatory neuropathies (NIN) was quantitated by immunohistochemistry. Results were correlated with clinical and electrophysiologic findings.
RESULTS: The production of MMP-2 and MMP-9 is increased in nerve tissue in CIDP and NSVN compared with NIN. T cells are the predominant source of MMP-2 and MMP-9 in CIDP and NSVN, whereas macrophages contribute only to a minor extent. Stromal cells of the perineurium/epineurium are an additional source of MMP-2 in NSVN, but not in CIDP. Expression of MMP-3 and MMP-7 was not detectable in CIDP or NSVN. Expression of MMP-2 and MMP-9 did not correlate with clinical disease activity and electrophysiologic measurements.
CONCLUSIONS: The upregulation of MMP-2 and MMP-9 is a specific feature of CIDP and NSVN, and selective inhibitors of these enzymes could be used to prevent inflammatory tissue damage. The similar increase of MMP-2 and MMP-9 in both demyelinating (CIDP) and nondemyelinating (NSVN) neuropathies raises doubts about whether MMPs play a primary role in demyelination.
This article has been cited by other articles:
|
|
 |
|
  C. Sommer, S. Koch, M. Lammens, A. Gabreels-Festen, G. Stoll, and K. V. Toyka Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP Neurology, December 27, 2005; 65(12): 1924 - 1929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Koller, B. C. Kieseier, S. Jander, and H.-P. Hartung Chronic Inflammatory Demyelinating Polyneuropathy N. Engl. J. Med., March 31, 2005; 352(13): 1343 - 1356. [Full Text] [PDF]
|
|
|
|
|
|
S. Jann, M. A. Bramerio, S. Beretta, S. Koch, C. A. Defanti, K. V. Toyka, and C. Sommer Diagnostic value of sural nerve matrix metalloproteinase-9 in diabetic patients with CIDP Neurology, December 9, 2003; 61(11): 1607 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Kieseier, M. C. Dalakas, and H.-P. Hartung Immune mechanisms in chronic inflammatory demyelinating neuropathy Neurology, December 24, 2002; 59(90126): S7 - 12. [Abstract] [Full Text]
|
|
|
|
|
|
K. Michizono, F. Umehara, T. Hashiguchi, K. Arimura, E. Matsuura, O. Watanabe, N. Fujimoto, Y. Okada, and M. Osame Circulating levels of MMP-1, -2, -3, -9, and TIMP-1 are increased in POEMS syndrome Neurology, March 27, 2001; 56(6): 807 - 810. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
